 5. Phase II: patients are eligible if their previous chemotherapy regimen did not contain bortezomib, carfilzomib, or other known proteasome inhibitor or a combination of gemcitabine 800 mgm2 plus adriamycin 30 mgm2. Patients who receive sequential or alternating therapy as part of front-line treatment will be counted as having one prior regimen. Patients who have failed prior neoadjuvant chemotherapy will be eligible for this trial. 